Guselkumab for pain in psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Pain, Skin clinical trials.
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have had psoriatic arthritis for at least 6 months
- Standard treatments like methotrexate or TNF inhibitors did not work or caused side effects
- You have active arthritis with at least one swollen wrist or knee
- You have pain rated >15 on a 0-100 scale and moderate-to-high disease activity (DAPSA >14)
- You are not pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing how well guselkumab works for people with psoriatic arthritis who are starting it in everyday medical practice. Researchers want to see if the drug helps reduce joint swelling and tenderness, and if it can improve enthesitis (pain where tendons attach to bone).
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
This study looks at whether the drug guselkumab can help people who have both psoriatic arthritis and non-alcoholic fatty liver disease (NAFLD). If you are starting guselkumab for your psoriatic arthritis and have a fatty liver, you may be able to join.
Hear when a new Psoriasis Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.